Skip to main content
Premium Trial:

Request an Annual Quote

Caliper Technologies, Pharmacopeia Added to Nasdaq Biotech Index

NEW YORK, May 14 – Caliper Technologies and Pharmacopeia will be among seven new companies included in the Nasdaq Biotechnology Index as of marketing opening May 21, Nasdaq announced on Monday. 

Companies included in the Index are evaluated semi-annually for minimum price, market value, and average daily share volume requirements.

Sixteen companies will be removed, including Lexicon Genetics. The Woodlands, Texas-based company on May 8 announced flat revenues first-quarter 2001 compared to the year-ago quarter.

Caliper, based in Mountain View, Calif., designs and manufactures lab-on-chip technologies. It had a market capitalization of $385 million at the time of selection.

Pharmacopeia of Princeton, NJ, has a drug discovery segment and recently merged its four software units into a single subsidiary called Accelrys. The company had a market capitalization of $23 million at the time of its selection.

The Nasdaq Biotechnology Index, which was started in 1993, increased 23 percent in 2000.

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.